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Abstract 
Aims: Calcineurin (CN) influences myosin phosphorylation and alters endothelial barrier 
function; however, the molecular mechanism is still obscure. Here we examine if CN controls 
myosin phosphorylation via mediating the phosphorylation state of Thr696 in myosin 
phosphatase (MP) target subunit 1 (MYPT1), the phosphorylation site inhibitory on the 
catalytic activity of MP. 
Methods and results: Exposure of bovine or human pulmonary artery endothelial cells 
(BPAEC or HPAEC) to the CN inhibitor cyclosporin A (CsA) induces a rise in intracellular 
Ca2+ and increases the phosphorylation level of cofilinSer3 and MYPT1Thr696 in a Ca2+ and Rho-
kinase dependent manner. Active catalytic fragment of CN overexpressed in tsA201 cells 
decreases endogenous MYPT-phospho-Thr696 (MYPT1pThr696) level. Purified CN 
dephosphorylates 32P-labeled MYPT1 suggesting direct action of CN on this substrate. 
Interaction of MYPT1 with CN is revealed by MYPT1 pull-down experiments and 
colocalization in both BPAEC and HPAEC as well as by surface plasmon resonance based 
binding studies. Stabilization of the MYPT1-CN complex occurs via the MYPT1300PLIEST305 
sequence similar to the CN substrate-docking PxIxIT-motif. Thrombin induces a transient 
increase of MYPT1pThr696 in BPAEC, while its combination with CsA results in maintained 
phosphorylation level of both MYPT1pThr696 and myosin. These phosphorylation events might 
correlate with changes in endothelial permeability since CsA slows down the recovery from 
the thrombin induced decrease of the transendothelial electrical resistance of BPAEC 
monolayer. 
Conclusions: CN may improve endothelial barrier function via inducing dephosphorylation 
of cofilinpSer3 and by interaction with MYPT1 and activating MP through MYPT1pThr696 
dephosphorylation, thereby affecting actin polymerization and decreasing myosin 
phosphorylation. A
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1. Introduction 
An important function of vascular endothelial cells is to maintain a selective barrier, thereby 
controlling the exchange of molecules and cells across the wall of blood vessels1. 
Physiological and/or pathological stimuli (e.g. inflammation, allergy, physical injury) may 
change the integrity of endothelial cells (EC) leading to the formation of gaps between the 
cells, thus compromising barrier function and increasing vessel permeability. The cytoskeletal 
and intercellular junction proteins of EC play an important role in the regulation of barrier 
integrity, and their physiological functions are often mediated by phosphorylation on 
Ser/Thr/Tyr residues2,3. These findings directed attention to uncover the types of protein 
kinases and phosphatases implicated in the phosphorylation of key endothelial proteins 
involved in the mediation of endothelial permeability4.  
 Actomyosin based contractility of EC is involved in the regulation of cell shape and 
stress fiber formation, which are major factors in the development of intercellular gaps during 
decreased barrier integrity5. The contraction of EC is elicited by increase in intracellular Ca2+ 
[Ca2+]i and in the phosphorylation of the 20 kDa regulatory light chain of nonmuscle myosin 
II (MLC20). The latter is balanced by the actual activity ratio of MLC20 kinases (MLCKs) 
and myosin phosphatase (MP)6.  
 MP consists of the δ isoform of protein phosphatase-1 (PP1) catalytic subunit (PP1cδ), 
PP1cδ-associated 130-133 kDa regulatory protein termed myosin phosphatase target subunit 1 
(MYPT1), and a 20 kDa protein bound to the C-terminal region of MYPT17. It is regulated 
via the RhoA/RhoA-activated kinase (ROK) pathway since ROK phosphorylates Thr696 and 
Thr853 in MYPT1 resulting in the inhibition of phosphatase activity8, 9. MP inhibition could 
also occur by a 17 kDa protein termed CPI-17 which is activated via phosphorylation at 
Thr38 by protein kinase C or ROK10. CPI-17 is expressed in EC and involved in histamine 
and thrombin induced barrier dysfunction11 as well as in antagonizing thrombin induced MP A
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inactivation by cAMP/PKA12. The level of phosphorylated MYPT1-Thr696 (MYPT1pThr696) 
reflects the activity status of MP and it is correlated with the extent of MLC20 
phosphorylation and the changes in endothelial permeability13-15. Thus, uncovering the 
physiological regulation of the phosphorylation status of MYPT1 may significantly contribute 
to understanding these processes. The kinases that phosphorylate MYPT1 at Thr696 are quite 
well characterized, while the phosphatases involved in dephosphorylation are much less 
understood. Protein phosphatase-2A (PP2A) and the Ca2+-calmodulin (CaM) dependent 
protein phosphatase, termed calcineurin (CN) or protein phosphatase-2B (PP2B), were 
considered as potential MYPT1 phosphatases acting on MYPT1pThr696 and MYPT1pThr853 as 
revealed by in vitro assays16. CN/PP2B has been implicated in the mediation of both myosin 
phosphorylation17 and endothelial permeability18, however its cellular targets are not 
unambiguously identified yet. 
 We showed recently that CN contributed to the recovery of EC from thrombin-induced 
barrier dysfunction, whereas pharmacological inhibition of CN by cyclosporin A (CsA) or 
FK506 prolonged the contractile effect and maintained gap formation between ECs19. The 
goals of the present study were to dissect the molecular mechanism by which CN may affect 
the contractile machinery with special interest in the mediation of MLC20 phosphorylation by 
the regulation of MP. Our present data suggest that CN is directly involved in the 
dephosphorylation of MYPT1 at both MYPT1pThr696 and MYPT1pThr853, and it influences the 
phosphorylation level of cofilin, too. It is concluded that CN mediates MLC20 
phosphorylation via regulation of MP and actin filament reorganization with a concomitant 
effect on endothelial permeability. Moreover, dephosphorylated MYPT1 and CN form a 
stable interaction which may have physiological implications in localizing these proteins to 
important signaling complexes.  
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2. Materials and methods 
 
2. 1 Materials 
Materials (chemicals and vendors) are given in Supplementary materials. 
 
2. 2 Proteins and antibodies 
Glutathione-S-transferase (GST)-coupled full-length MYPT1 (GST-MYPT11-1004) and a C-
terminal fragment (GST-MYPT1667-1004)8 or hexahistidine (His)-tagged N-terminal MYPT1 
fragments (His-MYPT11-633, His-MYPT11-296, His-MYPT1304-511)20 were expressed in E. coli 
and purified as described. PP1c and PP2Ac were purified from rabbit skeletal muscle21. 
Calcineurin was purified from bovine brain22.The antibodies and immunochemicals used are 
detailed in Supplementary materials.  
 
2. 3 Cell cultures, treatments and transfections 
BPAEC from American Type Tissue Culture Collection (Rockville, MD) and HPAEC from 
Clonetics (San Diego, CA) were cultured and utilized as previously described19. Cells were 
treated with effectors in serum-free medium. Cells of tsA201 were grown to 60-70% 
confluency and transfected with pEGFP, ∆CN-A/pEGFP, Flag-MYPT1, and CN-Aα/pEGFP 
plasmids using jetPEI transfection reagent according to the manufacturer’s instructions. Flow 
cytometry analysis and measurement of [Ca2+]i were carried out as given in Supplementary 
materials. 
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2. 4 Immunoblotting  
Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on 10-20% acrylamide gels and blotted onto nitrocellulose membranes23 which were 
exposed to the antibodies and analyzed as given in Supplementary materials.  
 
2. 5 Pull-down assays  
GST-MYPT1 pull-down from BPAEC lysates were performed as previously described24. 
Cells of tsA201 were transfected with Flag-peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys)-
coupled MYPT1 (Flag-MYPT1) or co-transfected with Flag-MYPT1 plus CN-Aα/pEGFP 
plasmids. Flag-MYPT1 as well as its associated proteins were isolated from cell lysates on 
anti-Flag resin according to the manufacturer’s recommendations. Resin-bound proteins were 
solubilized by boiling in SDS sample buffer and were subjected to Western blotting using 
anti-MYPT11-296, anti-CN-Aα, anti-PP1cδ and anti-GFP antibodies. 
 
2. 6 Dephosphorylation of 32P-labeled MYPT1 by CN, PP1c and PP2Ac 
GST-MYPT1 was phosphorylated by ROCK in the presence of [γ-32P]ATP and Mg2+ to an 
extent of 1.6 mol 32Pi/mol MYPT1 incorporation25. Phosphatase assays were accomplished as 
given in Supplementary materials. 
 
2. 7 Surface plasmon resonance 
Interaction of MYPT1 with CN was analyzed by surface plasmon resonance (SPR) using a 
Biacore 3000 instrument. GST- and His-tagged MYPT1 proteins were immobilized on CM5 
sensor chips and determination of the binding of CN or PP1c on these surfaces was performed 
as described23. Kinetic parameters and the association constant (Ka) values were extracted 
from the sensograms using BIAevaluation 3.1 software.  A
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2. 8 Measurement of transendothelial electrical resistance 
Transendothelial electrical resistance (TER) was measured dynamically across a confluent 
monolayer of BPAEC using an electrical cell-substrate impedance sensing system (ECIS; 
Applied Biophysics, Troy, NY) as described previously26. Decreases in monolayer resistance 
to electrical current flow, which correlated with paracellular gap formation, were measured 
according to the method described27.  
 
2. 9 Immunofluorescence and confocal microscopy 
BPAEC and HPAEC were prepared for immunofluorescence as described19 and were imaged 
on an Olympus Fluoview 1000 confocal microscope (Hamburg, Germany) using a 60× 
UPLSAPO (NA 1.35) oil immersion objective. Pearson’s correlation coefficients were 
determined as described28. 
 
2. 10 Statistical analysis 
Statistical significance of differences in measured variables between control and treated 
samples was determined by Student’s t-test or one-way ANOVA. Difference was considered 
significant at P < 0.05 and indicated as *p < 0.05, **p < 0.01 or ***p < 0.001. 
 
 
3. Results 
 
3. 1 Calcineurin dephosphorylates MYPT1 in endothelial and tsA201 cells 
Pharmacological inhibition of CN by CsA in cultured BPAEC (Fig. 1A) or HPAEC (Fig. 1B) 
resulted in a marked increase (~3.5-fold and 2.1–fold, respectively) in MYPT1pThr696, 
indicating that CN was involved in the dephosphorylation of this residue. H1152, a specific A
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ROK inhibitor, inhibited the CsA induced increase in MYPT1pThr696 suggesting the role of 
ROK in the phosphorylation process. CsA also increased MYPT1pThr853, but to a somewhat 
smaller extent than that of MYPT1pThr696 in both BPAEC and HPAEC (Fig. S1A and B, see in 
Supplementary materials) also in a ROK-dependent manner. Changes in endogenous 
MYPT1pThr696 were also determined (Fig. 1C) in tsA201 cells transfected with a plasmid 
coding for a pEGFP-coupled constitutively active CN-A form, in which the CaM binding and 
autoinhibitory domains were truncated (∆CN-A/pEGFP)19. The percent changes in 
MYPT1pThr696 were estimated by densitometry of Western blots and untransfected cells served 
as a control (100%). After overexpression of ∆CN-A/pEGFP or pEGFP alone MYPT1pThr696 
levels were 49±9 % and 142±41 % (n=3) compared to control, respectively, implying again 
the role of CN in MYPT1 dephosphorylation.  
 In in vitro phosphatase assays purified CN dephosphorylated recombinant GST-
MYPT1 substrate (32P-labeled at Thr696 and Thr853 via phosphorylation by ROK) in a dose 
and Ca2+-CaM dependent manner (Fig. 1D). The kinetics of dephosphorylation were similar 
to that of observed with PP1c and PP2Ac. These data suggested a direct action of CN on 
phosphorylated MYPT1.  
 The highly Ca2+-CaM dependent dephosphorylation of MYPT1 by CN raised a 
concern how CN inhibition by CsA may result in a robust increase in MYPT1pThr696 in 
unstimulated EC at presumably low  [Ca2+]i and CN activity. We examined the effect of CsA 
on [Ca2+]i of BPAEC and found that CsA evoked an increase in [Ca2+]i which was dependent 
on the presence of extracellular Ca2+ (Fig. 2A). Before addition of CsA values of 340/380 nm 
excitation ratio were 0.66±0.01 in the presence or 0.54±0.02 in the absence of extracellular 
Ca2+, i. e. in the presence of EGTA. The CsA induced increase in [Ca2+]i was transient, 
reaching a maximum within 2 min (1.71±0.30), then decreased, but still remained at a higher 
level (0.99±0.16) than the initial [Ca2+]i (Fig. 2B) till the end of the incubation period with A
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CsA. Increase in [Ca2+]i coupled with CN activation has been implicated in inducing the 
dephosphorylation of cofilin-phospho-Ser-3 (cofilinpSer3) via Slingshot phosphatase in HeLa 
cells29. Accordingly, when BPAEC or HPAEC was challenged with CsA an increase in 
cofilinpSer3 was observed (Fig. 2C and D) in both BPAEC and HPAEC. An apparent increase 
in the F-actin content of HPAEC was also seen by fluorescent microscopy (Fig. S3) 
highlighting another consequence of CN inhibition in EC. The necessity of elevated [Ca2+]i to 
increase MYPT1pThr696 was also assessed in BPAECs. In the absence of intracellular Ca2+, 
CsA had no effect on the level of MYPT1pThr696 (Fig. 2E).  
 
3. 2 Interaction of MYPT1 with CN as revealed by pull-down, coexpression and 
colocalization experiments 
Pull-down experiments with Flag-MYPT1 and GST-MYPT1 in tsA201 and EC lysates 
containing endogenous CN were carried out to analyze the physiological relevance of MYPT1 
and CN interaction. CN-Aα (Fig. 3A, left panel, and Fig. S2A) and PP1cδ (Fig. 3A, left) were 
identified as Flag-MYPT1 interacting proteins in tsA201 cells as judged by Western blots. 
When both Flag-MYPT1 and CN-Aα/pEGFP were coexpressed in tsA201 cells the 
coprecipitation of these proteins was also observed (Fig. S2B). Flag-MYPT1 isolated from 
tsA201 cells on anti-Flag resin (and freed of associated proteins) pulled down CN-Aα and 
PP1cδ from both BPAEC and HPAEC lysates (Fig. 3, middle and right panels) implicating 
that the interaction of MYPT1 and CN occurred at the cellular level and it was not obstructed 
by PP1c bound to MYPT1. Nonphosphorylated GST-MYPT1 pulled down the CN-Aα 
subunit from endothelial cell lysate (Fig. S2C) indicating that phosphorylation of MYPT1 is 
not necessary to the interaction. 
Confocal microscopy localized both CN-Aα and MYPT1 predominantly in the 
cytoplasm and to a lesser extent in the nucleus in BPAEC (Fig. 3B, left panels) and HPAEC A
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(Fig. 3B, right panels). The appearance of merged images suggested colocalization of these 
proteins in both cell types, which was confirmed by the determination of the Pearson’s 
correlation coefficients (see C values in legend to Fig. 3B). Thrombin treatment induced 
shape change and formation of gaps between the cells; however, it did not alter the extent and 
pattern of the colocalization of MYPT1 and CN. 
 
3. 3 Interaction of MYPT1 and CN assessed by surface plasmon resonance based 
binding experiments 
To clarify the molecular background for the formation of the CN-MYPT1 complex, binding 
of CN to full-length and truncated mutants of MYPT1 was determined in SPR-based 
experiments using purified proteins. Fig. 4A shows that CN bound to the full-length GST-
MYPT11-1004 surface in a concentration range of 1 to 5 µM. Assuming the formation of a 1:1 
complex an association constant of Ka=(1.86±1.37)x107 M-1 was derived from the binding 
curves. In contrast, CN hardly bound to the GST-MYPT1667-1004 surface resulting in only 
slight and “noisy” increase of the resonance signals even at higher, 5-10 µM CN 
concentrations (Fig. 4B) implying that the C-terminal region of MYPT1 is not a major 
determinant in the interaction. In contrast, the mutant representing the N-terminal half of 
MYPT1 (His-MYPT11-633) formed a similarly stable complex with CN (Ka= (1.06±0.04)x107 
M-1) to that of the full-length MYPT11-1004 (Fig. 4C). However, the association and 
dissociation kinetics appeared to be distinct, which may indicate different availability of the 
binding sites in these two proteins and/or reflect differences in the immobilization techniques. 
The binding of CN to His-MYPT11-296 (Fig. 4D) or His-MYPT1304-511 (Fig. 4E) resulted in 
less stable complexes with association constants of Ka=(3.14±1.06)x104 M-1 and 
Ka=(1.15±0.52)x105 M-1, respectively. 
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Possible competition between PP1c and CN was assessed since PP1c was also shown 
to bind to the N-terminal MYPT1 region. Fig. 4F shows that the response units obtained by 
injecting PP1c or CN alone until saturation were added up when the two proteins were 
applied in combination. Furthermore, CN was able to bind to the MYPT1 surface saturated 
with PP1c (Fig. 4G) confirming that binding of PP1c and CN to MYPT1 were not mutually 
exclusive. 
 
3. 4 Inhibition of CN by CsA sustains MYPT1 and myosin phosphorylation upon 
thrombin treatment accompanied with increased endothelial permeability 
It was established that during thrombin treatment of EC transient phosphorylation of MLC20 
occurs, which is coupled to transient inactivation of MP30. Changes in MYPT1Thr696 following 
thrombin stimulation were also transient peaking at 1 min and declining approximately to the 
initial level at 10 min (Fig. 5A). In contrast, when BPAEC was pretreated with CsA there was 
a marked increase in MYPT1pThr696 before addition of thrombin. This MYPT1pThr696 level 
decreased significantly (to about 75% of the maximal value) upon addition of thrombin, but it 
still remained sustained at this relatively high level (Fig. 5A, middle and lower panel). The 
most prominent difference between MYPT1pThr696 levels measured in the absence and 
presence of CsA upon addition of thrombin was observed at 10 min. Therefore we assessed 
phosphorylated MLC20-Ser19 (MLC20pSer19) in BPAEC in the absence and presence of CsA 
after 10 min after thrombin treatment. CsA or thrombin alone slightly increased MLC20pSer19, 
while a more significant increase occurred when thrombin was applied after CsA pretreatment 
(Fig. 5B). Similar patterns were observed in the changes of MLC20pSer19 in BPAEC by 
fluorescent staining (Fig 5C, left panel) following the above treatments. Quantification of 
MLC20pSer19 in the fluorescently labeled samples of BPAEC by flow cytometry analysis (Fig. 
5D) was reminiscent of the changes obtained by the densitometry of Western blots (Fig. 5B). A
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The appearance of actin filaments was also altered (Fig. 5C, middle panel). In the presence of 
CsA or thrombin the shape of the cells changed and the amount of the stress fibers increased 
while the combined application of CsA and thrombin resulted in the local enrichment of 
MLC20pSer19 and its colocalization with the cortical actin filaments. 
 Changes in the phosphorylation level of myosin are often reflected in altered 
endothelial barrier function. Transendothelial electrical resistance (TER) of BPAEC 
monolayers was determined by applying the same treatments as in the cell based assays of 
MYPT1 and MLC20 phosphorylation. Fig. 6A shows that CsA caused a rapid, significant 
decrease of TER for a prolonged period (~2 hours) before recovery. Thrombin alone induced 
also a fast and more pronounced decrease in TER than did CsA, however, the recovery 
appeared to be faster and completed in 45 min. Pretreatment of BPAEC with CsA before 
thrombin addition did not alter the extent of decrease in TER induced by thrombin; however, 
a sustained decrease in TER (~1.5 hour) was observed suggesting that CsA slowed down 
significantly the recovery of TER. The changes in TER of BPAEC reflect alterations in 
endothelial permeability paralleling in part the changes in MLC20pSer19 observed under the 
same conditions. 
 
4. Discussion 
Our present work identifies CN as a MYPT1 phosphatase acting directly, and in a Ca2+-CaM 
manner, on the PP1c inhibitory MYPT1pThr696 site. Dephosphorylation of MYPT1 by CN has 
been shown previously; however, its physiological relevance was doubted since cell lysates 
did not exhibit any Ca2+-CaM dependent activity assayed with phospho-MYPT1 substrate16. 
We provide evidence here for the direct interaction of CN with MYPT1, and the occurrence 
of the above dephosphorylation process at cellular level as the CN inhibitor CsA profoundly 
increases the MYPT1pThr696 level in EC and dephosphorylation of endogenous MYPT1pThr696 A
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occurs by an active truncated form of CN overexpressed in tsA201 cells. CsA induces a 
transient but partially maintained rise in [Ca2+]i dependent upon the presence of extracellular 
Ca2+ implicating plasma membrane Ca2+-channel(s) in this process (Fig. 6B). The precise 
mechanism of this Ca2+ influx with respect to the involvement of the type of channel(s) as 
well as the role of CsA-cyclophylin complex and/or its inhibitory influence on CN requires 
further investigations. The CsA induced [Ca2+]i transient is a prerequisite of the increase in 
MYPT1pThr696 as it is not observed in the absence of extracellular Ca2+. The rise in [Ca2+]i may 
also increase MYPT1pThr696 by the activation of ROK, since it was shown31 that increasing 
[Ca2+]i is coupled with enhancement of active RhoA (RhoA-GTP). Nevertheless, this 
enhanced [Ca2+]i does not seem to activate MLCKs to an extent that would significantly 
increase MLC20pSer19. On the other hand, phosphorylation of cofilinSer3, an actin-
depolymerizing factor, is elevated significantly in both BPAEC and HPAEC upon CsA 
treatment. Previous studies have shown29 that an increase in [Ca2+]i coupled with CN 
activation results in dephosphorylation and activation of Slingshot, a major cofilinpSer3 
phosphatase, thereby lowering cofilinpSer3. Elevated [Ca2+]i may also increase ROK activity, 
which activates LIM-kinase (a cofilin kinase), thus it contributes to enhancing cofilinpSer3. 
This elevation in cofilinpSer3 is further favored by CsA induced CN inhibition preventing 
activation of Slingshot, thus suppressing dephosphorylation. CofilinpSer3 has suppressed actin-
depolarizing activity; therefore a rise in cofilinpSer3 may contribute to increased F-actin content 
and actin-filament reorganization in EC. 
 The level of MYPT1pThr696 is a key factor in the activity status of MP and it controls 
MLC20 phosphorylation. CN was shown to associate with the cytoskeletal (myosin-rich) 
fraction of EC17 and was phosphorylated and activated upon thrombin stimulation resulting in 
dephosphorylation of EC proteins. In contrast, in the presence of CN inhibitors EC protein 
dephosphorylation including MLC20pSer19 was attenuated. Our results support a mechanism in A
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which CN counterbalances the phosphorylation of the inhibitory site(s) in MYPT1 keeping 
MP in an active state, thereby decreasing MLC20pSer19. Thrombin triggers a rise in [Ca2+]i 
which activates both MLCKs and CN resulting in transient MLC20 phosphorylation and MP 
inhibition30. Our present data imply that the transient MP inhibition is coupled with a transient 
increase in MYPT1pThr696 (Fig. 5). The role of CN in mediating MYPT1pThr696 
dephosphorylation during thrombin stimulation is confirmed by the findings that pretreatment 
of EC with CsA results in partially sustained phosphorylation of both MYPT1pThr696 and 
MLC20pSer19. The role of PP1c and PP2Ac in MYPT1pThr696 dephosphorylation is also shown 
by in vitro phosphatase assays, but in cells they may act in holoenzyme forms, which are still 
not identified. Nevertheless, PP2A have been implicated in MYPT1 dephosphorylation, since 
PP2A-specific inhibition using cell-permeable phosphatase inhibitory toxins (okadaic acid 
and calyculin-A) profoundly enhanced both MYPT1pThr696 and MYPT1pThr853 in HepG232 and 
THP-1 cells23. These “CsA insensitive” PP2A (and PP1) enzymes may have a role in the 
partial decrease of MYPT1pThr696 during CsA plus thrombin treatment with a concomitant 
effect on MLC20pSer19.  
 It was shown that CN inhibitors (CsA, FK506, deltamethrin) influence EC 
permeability. FK506 alone did not alter TER, but it prevented the reversal of thrombin-
induced decrease in resistance, while PP1 and PP2A inhibitors were without effect18. The 
effect of FK506 was attributed to a CN-inhibition dependent increase in the phosphorylation 
of protein kinase Cα. Inhibition of CN by deltamethrin also increased endothelial 
permeability and it was due to enhanced MLC20 phosphorylation17. Our results suggest that 
CN inhibition by CsA decreases TER in BPAEC to a significant extent without a profound 
change in MLC20 phosphorylation. We hypothesize that this change in TER by CsA is due to 
an increase in cofilinpSer3 resulting in enhanced actin polymerization with subsequent 
alterations in EC cell shape and permeability. CsA treatment also slows down the recovery of A
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decreased TER induced by thrombin and this effect appears to parallel the sustained level of 
MYPT1pThr696 and MLC20pSer19. Our data imply that CN inhibition by CsA exerts both 
MLC20 phosphorylation-dependent and independent effects. 
 Our finding that CN forms a stable complex with dephosphorylated MYPT1 indicates 
that the interaction between these two proteins is stronger than it would be expected for a 
simple enzyme-phosphosubstrate adduct. SPR-binding studies establish the essential role of 
the N-terminal region of MYPT1 in the interaction with CN. Accordingly, there is a CN-
substrate-docking PxIxIT-like motif33 in the N-terminal region of MYPT1 (300PLIEST305), 
which may play an important role in the interaction with CN. Thus, MYPT1 fragments 
(MYPT11-296 and MYPT1304-511) lacking this motif bind to CN with lower affinity (Ka~104-
105) than that of the mutant representing the N-terminal half (MYPT11-633) or the full-length 
(MYPT11-1004) protein (Ka~107). Nevertheless, MYPT11-296 and MYPT1304-511 still exhibit 
significant binding to CN suggesting that beside the PxIxIT-like docking motif further regions 
within these fragments are also involved in forming a stable MYPT1-CN complex. PP1c 
binds also to the N-terminal regions of MYPT134, but the major docking site for PP1c in 
MYPT1 (35KVKF38) is different from that of CN (300PLIEST305). Further competitive binding 
sites for PP1c and CN could also be excluded as the two proteins coprecipitate with Flag-
MYPT1 during pull-downs and bind independently to MYPT1 surface in SPR binding studies 
suggesting that CN presumably interacts with the MP holoenzyme with the same affinity as 
does with MYPT1. 
 In summary, we identified a mechanism how CN may modulate the phosphorylation 
level of MLC20 in myosin via influencing the phosphorylation state of a PP1c inhibitory site 
in the MYPT1 subunit of MP. It is assumed that these CN-induced changes of the 
phosphorylation status of MLC20 and MYPT1 are also reflected in the contractile features of 
EC and in the alterations of barrier function. The relatively strong interaction formed between A
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CN and MYPT1 (and the MP holoenzyme) may have broader physiological significance in 
localizing these enzymes close to their possible substrates forming functionally important 
signaling complexes. 
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LEGENDS TO FIGURES 
 
Figure 1. CN is involved in the control of the phosphorylation level of MYPT1Thr696. 
Confluent BPAEC (A) or HPAEC (B) were incubated in the absence (control) or in the 
presence of 2 µM CsA, 10 µM H1152 or 10 µM H1152 followed by 2 µM CsA for 30 min..C: 
Effect of overexpression of a constitutively active, truncated CN form (∆CN-A/pEGFP) on 
MYPT1pThr696 level in tsA201 cells. Cells were lysed, boiled in SDS sample buffer and 
subjected to Western blot analysis using anti-MYPT1pThr696, anti-MYPT11-296 and anti-tubulin 
antibodies. The results shown are representative blots of three independent experiments 
(upper panels). Densitometry of the MYPT1pThr696 bands normalized for the respective bands 
of MYPT1 or tubulin loading controls were carried out to quantify changes in MYPT1pThr696 
(A, B: lower panels). D: Dephosphorylation of 32P-MYPT1 by CN, PP1c and PP2Ac. The 
release of 32Pi from 0.5 µM 32P-MYPT1 (1.6 mol phosphate/mol MYPT1) by PP1c, PP2Ac 
and CN was determined at the indicated phosphatase concentrations and time intervals. CN 
was assayed in the absence (at 72 nM) or presence (18, 36 and 72 nM) of 0.2 mM Ca2+ and 40 
µg/ml CaM. The results are expressed as pmol 32Pi released from 32P-MYPT1 (mean±SEM of 
three independent experiments).  
 
Figure 2. 
Effects of CsA on [Ca2+]i and on phosphorylation of cofilinSer3 and MYPT1Thr696. BPAECs 
were treated with 2 µM CsA for 30 min at room temperature. A: Changes in [Ca2+]i upon 
addition of CsA were recorded with Fura-2 Ca2+ sensitive dye. Values for individual cells 
were calculated and the average response of 22-26 cells in a single representative experiment 
are shown in the presence (+Ca2+/-EGTA) or absence (-Ca2+/+EGTA) of extracellular Ca2+. 
B: Bars represent the average responses (values of 340/380 nm excitation ratio) ± SEM of 92-99 
cells from 4-7 independent determinations, each containing 22-26 individual cells. C and D: A
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Effect of CsA on the phosphorylation of cofilinSer3 assessed in BPAEC (C) and HPAEC (D) 
by Western blotting with anti-cofilinpSer3 antibody and anti-tubulin as loading control. E: 
Effect of CsA on the phosphorylation of MYPT1Thr696 in BPAEC in the absence of 
extracellular Ca2+.  
 
Figure 3. Interaction of MYPT1 with CN as revealed by pull-down assays and colocalization 
using confocal microscopy. A: Coprecipitation of MYPT1, PP1cδ and CN-Aα from tsA201, 
BPAEC and HPAEC lysates in Flag-MYPT1 pull-down assays. The bound proteins were 
analyzed by Western blotting by cutting the membranes into three pieces and then exposing 
them to the respective antibodies. The results shown are representative blots of three 
independent experiments. B: BPAEC (left panels) or HPAEC (right panels) were stained with 
anti-CN-Aα (green, left) or monoclonal anti-MYPT1 (red, middle) antibodies as described in 
the Supplementary material, and the images were merged (right) to assess colocalization. 
Pearson’s correlation coefficients (C values) calculated between the pixel intensities of the 
green and red channels were: C=0.72±0.09 (n=21) and C=0.71±0.04 (n=11) for control and 
thrombin-treated BPAEC, while C=0.86±0.06 (n=20) and C=0.75±0.08 (n=17) for control 
and thrombin-treated HPAEC, respectively. Scale bars: 10 µm. 
 
Figure 4. Characterization of the interaction between CN and MYPT1 by SPR-based binding 
assays. Full-length GST-MYPT11-1004 (A, F, G), GST-MYPT1667-1004 C-terminal fragment (B) 
and His-MYPT11-633 (C), His-MYPT11-296 (D) and His-MYPT1304-511 (E) N-terminal 
fragments were immobilized on CM5 chips coupled with anti-GST (A, B, F and G) or via 
direct amine coupling (C, D, E). CN (A-G) or PP1cδ (F, G), or PP1c plus CN (F, G) was 
injected over the surfaces at concentrations indicated on the sensograms. Sensograms were 
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obtained using Biacore 3000. Representative sensograms of 2-3 independent experiments 
with similar results are shown. 
Figure 5. Effect of CN inhibition by CsA on thrombin-induced phosphorylation of 
MYPT1Thr696 and MLC20Ser19. Confluent cells were preincubated without or with 2 µM CsA 
for 30 min and then stimulated with 50 nM thrombin for different intervals. Cells were lysed 
and analyzed by Western blotting using anti-MYPT1pThr696 and anti-MYPT11-296 antibodies at 
0, 1, 2 and 10 min after thrombin treatment (A), or with anti-MLC20pSer19 and anti-MLC20 
antibodies 10 min after thrombin treatment (B). The results shown are representative blots of 
three independent experiments. The densitometric data are mean±SEM (n=3). C: BPAEC 
were treated with none (control), with 2 µM CsA for 30 min, 50 nM thrombin for 10 min or 2 
µM CsA for 30 min followed by 50 nM thrombin for 10 min. Cells were stained with anti-
MLC20 pSer19 antibody and Texas Red-phalloidin. Scale bars: 10 µm. D: Quantification of 
MLCpSer19 in fluorescent labeled samples by flow cytometry after the indicated treatments. 
 
Figure 6. 
Influence of CsA on endothelial barrier function. A: Effect of CsA on transendothelial 
electrical resistance (TER) of BPAEC monolayers. Confluent monolayers of BPAEC grown 
on electrodes were challenged with none, 2 µM CsA or 50 nM thrombin, or with their 
combination adding thrombin to the cells after 30 min preincubation with 2 µM CsA 
(additions are indicated by arrows). TER was determined as described in Materials and 
Methods. Data shown are representative graphs of three experiments with similar results. B: 
Depiction of the mechanisms via CsA may affect endothelial permeability in EC (see 
explanations in the Discussion). 
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